Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Sitagliptin combined with diabetes drugs improves glycaemic control

  • Comment

A series of studies have backed the use of sitagliptin in combination with other drugs to help improve glycaemic control in patients with type 2 diabetes.

Poster presentations at the American Diabetes Association Annual Scientific Sessions in New Orleans this week show promising results for sitagliptin (Januvia) when used in combination with either metformin or insulin.

One study, a 44-week randomised trial, involved 1,250 patients with an average HbA1c baseline of 9.8% and no prior diabetes drug treatment.

The intervention group of 560 patients, who received sitagliptin/metformin (Janumet), showed average HbA1c reductions of 2.4%, after 18 weeks compared with 1.8% for patients taking metformin alone.

A second 24-week study of 564 patients on long-acting, intermediate-acting or pre-mixed insulin - with without metformin - the addition of sitagliptin reduced HbA1c by 0.6%, compared with placebo.

However a higher incidence of adverse events were reported with the addition of sitagplitin compared with placebo, mainly due to increases in hypoglycaemia (15.5% versus 7.8%), although this is to be expected with anti-hyperglycaemic drugs in combination with insulin.

None of these treatments are yet licensed for use in the UK.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.